摘要
目的分析人表皮生长因子受体-2(HER2)、雌激素受体(ER)和孕激素受体(PR)在乳腺癌组织中的表达,并用荧光免疫杂交法(FISH)检测乳腺癌组织中HER2基因扩增状态,评价其临床病理意义。方法应用FISH、IHC方法分析95例乳腺癌HER2基因扩增与临床病理特征的关系,比较两者之间的差异。结果 IHC法HER2蛋白表达(+++)12例中12例(100%)HER2基因扩增;HER(2++)50例中14例(28%)HER2基因扩增;HER2(+)21例中2例(9.52%)HER2基因扩增;84例浸润性导管癌中28例(33.3%)有HER2基因扩增,11例浸润性小叶癌中无HER2基因扩增;HER2基因扩增与ER和PR的IHC表达(+)或(-)间的差异有统计学意义(P<0.05);与肿瘤大小间的差异有统计学意义(P<0.05)。结论免疫组化检测可作为HER2表达状态的初筛,在IHC法HER蛋白表达(+++)同时ER、PR阴性的浸润性导管癌HER2基因扩增率较高。
Objective To investigate the expression of human epidermal growth factor receptor-2（HER2）,estrogen receptor（ER）and progesterone receptor（PR）in breast cancer,and detect state of HER2 amplification in breast cancer and assess its clinicopathological significance.Methods Immunohistochemistry and fluorescence in situ hybridization were used to detect HER2 protein/amplification expression status in 95 cases of breast cancer specimens,and the relationship with clinicopathological characters,and compared the difference between the two methods.Results Twelve of the 12 cases（100%）with HER2（3＋）by IHC was HER2 amplification by FISH testing;Forteenth of the 50 cases（28%）with HER2（2＋）by IHC was HER2 amplification by FISH testing;Two of the 21 cases（9.52%）with HER2（1＋）by IHC was HER2 amplification by FISH testing;Twenty-eight of the 84 cases（33.3%）of 84 cases with invasive ductal carcinomas identified HER2 amplification,11 cases with invasive lobular carcinomas identified no HER2 amplification;HER2 gene amplification and ER and of PR IHC expression（＋）or（-）the differences between a statistically significant（P0.05）;The expression of HER2 had significant difference with tumor size（P0.05）;Conclusion The immunohistochemical detection can be used in initial screening of HER2 protein expression,the presencen of HER2 amplification rate was higher in invasive ductal carcinoma,negative ER,PR and HER（3＋）expression by IHC.
出处
《当代医学》
2012年第31期8-10,共3页
Contemporary Medicine
关键词
乳腺癌
荧光原位杂交
免疫组织化学
人表皮生长因子受体-2
Breast cancer
Fluorescence in stiu hybridization
Immunohistochemistry
Human epidermal growth factor receptor-2
